DK2884978T3 - Nye Kappa-opioidligander - Google Patents

Nye Kappa-opioidligander Download PDF

Info

Publication number
DK2884978T3
DK2884978T3 DK13829428.5T DK13829428T DK2884978T3 DK 2884978 T3 DK2884978 T3 DK 2884978T3 DK 13829428 T DK13829428 T DK 13829428T DK 2884978 T3 DK2884978 T3 DK 2884978T3
Authority
DK
Denmark
Prior art keywords
kappa opioid
opioid ligand
new kappa
new
ligand
Prior art date
Application number
DK13829428.5T
Other languages
Danish (da)
English (en)
Inventor
Edward Roberts
Miguel A Guerrero
Mariangela Urbano
Hugh Rosen
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK2884978T3 publication Critical patent/DK2884978T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DK13829428.5T 2012-08-16 2013-08-16 Nye Kappa-opioidligander DK2884978T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683861P 2012-08-16 2012-08-16
PCT/US2013/055313 WO2014028829A1 (en) 2012-08-16 2013-08-16 Novel kappa opioid ligands

Publications (1)

Publication Number Publication Date
DK2884978T3 true DK2884978T3 (da) 2019-09-30

Family

ID=50101521

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13829428.5T DK2884978T3 (da) 2012-08-16 2013-08-16 Nye Kappa-opioidligander

Country Status (8)

Country Link
US (4) US9682966B2 (enExample)
EP (2) EP3584246A1 (enExample)
JP (3) JP6254163B2 (enExample)
AU (3) AU2013302497A1 (enExample)
CA (1) CA2882132C (enExample)
DK (1) DK2884978T3 (enExample)
ES (1) ES2750640T3 (enExample)
WO (1) WO2014028829A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302497A1 (en) 2012-08-16 2015-03-05 The Scripps Research Institute Novel kappa opioid ligands
US10982041B2 (en) * 2016-02-25 2021-04-20 Swancor Advanced Materials Co., Ltd. Epoxy resin oligomer
ES2908801T3 (es) 2016-06-07 2022-05-04 Jacobio Pharmaceuticals Co Ltd Nuevos derivados heterocíclicos útiles como inhibidores de SHP2
CA3056426A1 (en) 2017-03-17 2018-09-20 Edward Roberts Quinolinyl compounds and their use as a kappa opioid receptor (kor) antagonists and products and methods related thereto
HRP20241239T1 (hr) 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EP3723751A4 (en) * 2017-12-08 2021-07-07 The Rockefeller University KAPPA PYRANO [3,4-B] PYRAZINE OPIOID RECEIVER LIGANDS FOR THE TREATMENT OF ADDICTION, PRURITUS, PAIN AND INFLAMMATION
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN121002011A (zh) * 2023-02-17 2025-11-21 斯克里普斯研究学院 充当κ-阿片受体拮抗剂的喹啉衍生物
WO2024216061A1 (en) 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia
WO2024216046A1 (en) 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2025042657A1 (en) * 2023-08-18 2025-02-27 The Scripps Research Institute Kappa-opioid receptor antagonists
WO2025051204A1 (zh) * 2023-09-05 2025-03-13 海思科医药集团股份有限公司 一种kor拮抗剂及其在医药上的应用
WO2025250535A1 (en) 2024-05-28 2025-12-04 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia
WO2025257758A1 (en) 2024-06-11 2025-12-18 Assia Chemical Industries Ltd. Solid state forms of navacaprant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014171A1 (de) * 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
ATE172201T1 (de) * 1992-01-23 1998-10-15 Toray Industries Morphinan-derivate und medizinische verwendung
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
US6562827B1 (en) 1998-04-20 2003-05-13 Abbott Laboratories Heterocyclically substituted amides used as calpain inhibitors
US6284769B1 (en) 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
CA2537916A1 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
CA2551037A1 (en) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
JP4880583B2 (ja) 2004-03-17 2012-02-22 ファイザー・プロダクツ・インク 新規なベンジル(ベンジリデン)−ラクタム誘導体
DE602005023763D1 (de) * 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GB0510204D0 (en) * 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
NZ593684A (en) 2005-10-19 2012-11-30 Gruenenthal Chemie Novel vanilloid receptor ligands and their use for producing medicaments
CA2626496A1 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
AU2007320906A1 (en) * 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2009076387A1 (en) 2007-12-10 2009-06-18 Glaxo Group Limited Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011025799A1 (en) * 2009-08-26 2011-03-03 Glaxo Group Limited Cathepsin c inhibitors
WO2011050198A1 (en) * 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EA023293B1 (ru) * 2009-12-29 2016-05-31 Сувен Лайф Сайенсиз Лимитед ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
JP5935154B2 (ja) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Gpr119モジュレーターとしてのn−シクロプロピル−n−ピペリジニルベンズアミド
AU2013302497A1 (en) 2012-08-16 2015-03-05 The Scripps Research Institute Novel kappa opioid ligands

Also Published As

Publication number Publication date
EP2884978A4 (en) 2016-01-13
JP6254163B2 (ja) 2017-12-27
AU2013302497A1 (en) 2015-03-05
US20150210673A1 (en) 2015-07-30
CA2882132A1 (en) 2014-02-20
US20250066336A1 (en) 2025-02-27
ES2750640T3 (es) 2020-03-26
EP2884978A1 (en) 2015-06-24
US20250346584A1 (en) 2025-11-13
JP2015531764A (ja) 2015-11-05
AU2019246921B2 (en) 2021-04-01
CA2882132C (en) 2021-07-06
JP2018058873A (ja) 2018-04-12
EP2884978B1 (en) 2019-07-17
AU2019246921A1 (en) 2019-10-31
AU2018201522A1 (en) 2018-03-22
US20180099954A1 (en) 2018-04-12
JP2020090518A (ja) 2020-06-11
EP3584246A1 (en) 2019-12-25
US9682966B2 (en) 2017-06-20
WO2014028829A1 (en) 2014-02-20
US10118915B2 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
DK2884978T3 (da) Nye Kappa-opioidligander
DK2874736T3 (da) Automatiseret opløsningsdispenser
DK2776436T3 (da) Nye forbindelser
BR302012005490S1 (pt) Configuracao aplicada a tablet
BR302012005488S1 (pt) Configuracao aplicada a tablet
BR302012005492S1 (pt) Configuracao aplicada a tablet
LT2903991T (lt) Antifibroziniai piridinonai
DK2684610T4 (da) Bruser
EP2880683A4 (en) BVA INTERPOSER
DK2755963T3 (da) Nye dihydroquinolin-2-on-derivater
JP2012236821A5 (ja) 有機金属錯体
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
EP2912485A4 (en) POSITIONING
DE102013108016A8 (de) Sicherheitshülle
IL239447A0 (en) Novel compounds
EP2900475A4 (en) Drop detection
CL2012002088S1 (es) Dispensador
EP2809729A4 (en) Siloxane polyether copolymers
DK2692448T3 (da) Brusehoved
EP2896338A4 (en) SHOWER UNIT
DE112012006872T8 (de) Numeriksteuervorrichtung
BR302013002456S1 (pt) Dispensador
EP2877291A4 (en) Rotary nozzle
HUE053273T2 (hu) Opioid készítmények